Cargando…

Venous thrombotic events in severe and critically COVID-19 patients despite high dose prophylactic low-molecular-weight heparin

Hypercoagulation is one of the most distinct prognostic factors of patients with COVID-19 and has been associated with arterial thrombosis and other venous thrombotic events (VTE). Bleeding complications are far less encountered. The International Society on Thrombosis and Haemostasis (ISTH) guidanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Visser, Chantal, Sprenger, Reinier A., van den Bout, Hans J., Boer, Dirk P., el Moussaoui, Rachida, den Hollander, Jan G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434635/ http://dx.doi.org/10.1016/j.tru.2020.100006

Ejemplares similares

Extensive Thrombosis in a Severe COVID-19 Patient Despite Prophylactic Low Molecular Weight Heparin
por: Elkattawy, Sherif, et al.
Publicado: (2020)

The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy
por: Zou, Peimei, et al.
Publicado: (2019)

A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency
por: Atiq, Ferdows, et al.
Publicado: (2015)

Major Thrombotic Event Despite Anticoagulation in a Patient With COVID-19
por: Ataallah, Basma, et al.
Publicado: (2020)

Do Inpatients Receive Risk-Based Prophylactic Treatment for Thrombotic Events?
por: Nemani, Armin, et al.
Publicado: (2021)

A Case of COVID-19 Complicated by Venous Thromboembolism Despite Being on Prophylactic Anticoagulation
por: Rout, Amit, et al.
Publicado: (2020)

High-flow Nasal Cannula therapy: A feasible treatment for vulnerable elderly COVID-19 patients in the wards
por: van Steenkiste, Job, et al.
Publicado: (2021)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events
por: Glueck, Charles J., et al.
Publicado: (2018)

A direct comparison of prophylactic low-molecular-weight heparin versus unfractionated heparin in neurosurgery: A meta-analysis
por: Macki, Mohamed, et al.
Publicado: (2019)

Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007)

Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis
por: Lu, Xin, et al.
Publicado: (2018)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Subcutaneous hematomas from prophylactic heparin use
por: Koratala, Abhilash, et al.
Publicado: (2017)

Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients
por: Stattin, K., et al.
Publicado: (2020)

Prophylactic anticoagulation with low molecular weight heparin in COVID-19: cohort studies in Denmark and Sweden
por: Lund, Lars Christian, et al.
Publicado: (2022)

Prophylactic anticoagulant therapy for reducing the risk of stroke and other thrombotic events in COVID-19 patients
por: Aghamohammadi, Mehdi, et al.
Publicado: (2020)

Prevention of Venous Thrombotic Events in Brain Injury: Review of Current Practices
por: Glassner, Stuart, et al.
Publicado: (2013)

Prophylaxis and Therapy of Venous Thrombotic Events (VTE) in Pregnancy and the Postpartum Period
por: Sucker, Christoph
Publicado: (2020)

Effects of low molecular weight heparin and fondaparinux on mortality, hemorrhagic and thrombotic complications in COVID-19 patients
por: Fragkou, Paraskevi C., et al.
Publicado: (2022)

Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion
por: Lutfi, Forat, et al.
Publicado: (2020)

Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review
por: Cryer, Michael Joseph, et al.
Publicado: (2022)

Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis
por: Zhang, Wentao, et al.
Publicado: (2022)

Recurrent arterial and venous thrombosis in a 16-year-old boy in the course of primary antiphospholipid syndrome despite treatment with low-molecular-weight heparin: a case report
por: Biernacka-Zielinska, Malgorzata, et al.
Publicado: (2013)

Risk marker associations with venous thrombotic events: a cross-sectional analysis
por: Golomb, Beatrice A, et al.
Publicado: (2014)

Venous thrombotic events in psoriasis patients: a systematic review with meta-analysis
por: Hillary, Tom, et al.
Publicado: (2021)

Thrombotic Events in COVID-19 Are Associated With a Lower Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity
por: Clark, Chantal C., et al.
Publicado: (2021)

Thrombotic Venous Diseases of the Liver
por: Sabol, Timothy P., et al.
Publicado: (2015)

Low molecular weight heparin versus unfractionated heparin in the management of cerebral venous thrombosis: A systematic review and meta-analysis
por: Qureshi, Anjum, et al.
Publicado: (2017)

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
por: van der Wall, Sake J., et al.
Publicado: (2018)

Safety and Feasibility of Subcutaneous Low Molecular Weight Heparin for Cerebral Venous Sinus Thrombosis
por: Kim, Ji Seon, et al.
Publicado: (2005)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease
por: Olivera, Pablo A., et al.
Publicado: (2021)

Timing of Heparin Administration Modulates Arterial Occlusive Thrombotic Response in Rats
por: Matrai, Amanda B., et al.
Publicado: (2020)

Coronary angioplasty and COVID-19: are heparin requirements and thrombotic complications increasing?
por: Crane, H, et al.
Publicado: (2021)

Incidence of venous thrombotic events and events of special interest in a retrospective cohort of commercially insured US patients
por: Weller, Susan C, et al.
Publicado: (2022)

A Case of Hemorrhagic Myositis Associated With Prophylactic Heparin Use in Dermatomyositis
por: Bartl, Mery, et al.
Publicado: (2023)

Reducing the level of postoperative thrombotic complications by the combination of low molecular weight heparin and epidural anesthesia at the patients after total hysterectomy
por: Tarabrin, O, et al.
Publicado: (2012)

Bleeding Risk during Treatment of Acute Thrombotic Events with Subcutaneous LMWH Compared to Intravenous Unfractionated Heparin; A Systematic Review
por: Costantino, Giorgio, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_061q84f57dqt7oi6psj1ts2voa